Canagliflozin and Cardiovascular disease- results of the CANVAS trial

Canagliflozin is a new novel oral antidiabetic agent belonging to the class of sodium–glucose co-transporter 2 (SGLT2) inhibitors, inhibiting glucose reabsorption in the proximal tubule, leading to increased urinary glucose excretion and subsequently to reduction in plasma glucose concentration, in...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Community Hosp Intern Med Perspect
Hlavní autoři: Shah, Syed Raza, Najim, Najla Issa, Abbasi, Zainab, Fatima, Mazia, Jangda, Ayesha Altaf, Shahnawaz, Waqas, Shahid, Maira, Shah, Syed Arbab
Médium: Artigo
Jazyk:Inglês
Vydáno: Taylor & Francis 2018
Témata:
Perspective
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6197007/
https://ncbi.nlm.nih.gov/pubmed/30357039
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/20009666.2018.1521245
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky